The present knowledge of the physiology of H-Y antigen has been reviewed. It would appear that the results that have been obtained contradict one another and this brings into doubt the role that this antigen plays in testicular differentiation and the link it has with the Y chromosome.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Robust circulating microRNA signature for the diagnosis and early detection of pancreatobiliary cancer.
BMC Med
January 2025
Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan.
Background: A new circulating biomarker superior to carbohydrate antigen 19-9 (CA19-9) is needed for diagnosing pancreatobiliary cancer (PBca). The aim of this study was to identify serum microRNA (miRNA) signatures comprising reproducible and disease-related miRNAs.
Methods: This multicenter study involved patients with treatment-naïve PBca and healthy participants.
Optimized circular RNA vaccines for superior cancer immunotherapy.
Theranostics
January 2025
Department of Integrative Oncology, Fudan University Shanghai Cancer Center, and Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.
Circular RNA (circRNA) has gained attention as a promising platform for mRNA vaccines due to its stability, sustained protein expression, and intrinsic immunostimulatory properties. This study aimed to design and optimize a circRNA cancer vaccine platform by screening for efficient internal ribosome entry sites (IRES) and enhancing circRNA translation efficiency for improved cancer immunotherapy. We screened 29 IRES elements to identify the most efficient one for immune cell translation, ultimately discovering the A (EV-A) IRES.
View Article and Find Full Text PDFCD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells.
Cell Rep Med
January 2025
Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou 311121, China; Institute of Hematology, Zhejiang University, Hangzhou 310058, China; Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou 310058, China. Electronic address:
Clinical application of autologous chimeric antigen receptor (CAR)-T cells is complicated by limited targeting of cancer types, as well as the time-consuming and costly manufacturing process. We develop CD70-targeted, induced pluripotent stem cell-derived CAR-natural killer (NK) (70CAR-iNK) cells as an approach for universal immune cell therapy. Besides the CD70-targeted CAR molecule, 70CAR-iNK cells are modified with CD70 gene knockout, a high-affinity non-cleavable CD16 (hnCD16), and an interleukin (IL)-15 receptor α/IL-15 fusion protein (IL15RF).
View Article and Find Full Text PDFTransgenic αβ TCR tonic signaling is leukemogenic while strong stimulation is leukemia-suppressive.
J Leukoc Biol
November 2024
i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
The pre-T cell receptor (TCR) and TCR complexes are frequently expressed in T-cell acute lymphoblastic leukemia (T-ALL), an aggressive T cell precursor malignancy. Although mutations in TCR components are infrequent in T-ALL, earlier research indicated that transgenic αβ TCR expression in mouse T cell precursors promoted T-ALL development. However, we recently found that stimulation of TCR signaling in T-ALL induced leukemic cell apoptosis and suppressed leukemia.
View Article and Find Full Text PDFLong-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed/refractory multiple myeloma.
Mol Ther
November 2024
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Key Laboratory of Vascular Aging, Ministry of Education, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei 430030, China. Electronic address:
Article Synopsis
- CT103A is a human chimeric antigen receptor T cell therapy aimed at treating patients with relapsed/refractory multiple myeloma, presenting updated safety and efficacy outcomes.
- During long-term follow-up (median 45 months), all 18 patients experienced partial or better responses, with 77.8% achieving complete or stringent complete responses.
- The study showed promising survival rates, with a median progression-free survival of 22.6 months and overall survival of 50.2 months, indicating sustained benefits from CT103A treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!